Therefore, differentiating naïve CD4+ T cells into Th1 without blocking the B7-CTLA-4 interaction may potentially lead to a reduction in the clinically observed side effects while still maintaining strong anti-tumor efficacy. The gene discussed is CD4; the disease is neoplasm.